Science News
from research organizations

New biomarkers for the diagnosis of Alzheimer’s

Date:
February 4, 2015
Source:
Asociación RUVID
Summary:
Medical researchers have found new biomarkers for the clinical diagnosis of Alzheimer's disease. In this study, the authors have identified the amyloid precursor protein (APP) in its complete form unprocessed in the cerebrospinal fluid.
Share:
FULL STORY

A team at the Institute of Neurosciences, joint centre of the Miguel Hernández University (UMH) in Elche and the Spanish National Research Council (CSIC), has published in the online edition of the journal Molecular Neurodegeneration the paper “Heteromers of amyloid precursor protein in cerebrospinal fluid.” This project studies the validation of new biomarkers for the clinical diagnosis of Alzheimer's disease. The head researcher is Javier Sáez Valero, Professor of the Department of Biochemistry and Molecular Biology at the UMH.

In this study, the authors have identified the amyloid precursor protein (APP) in its complete form unprocessed in the cerebrospinal fluid. The complete form of the protein coexists in the cerebrospinal fluid with its fragments (referred to as sAPPβ and sAPPα) which had been proposed as diagnostic markers. All these forms of APP make mixed or heteromeric complexes. The researchers thus demonstrate that many of the previous studies aimed to determine sAPPβ or sAPPα separately, do not determine these biomarkers in a suitable way, as although the work had aroused great interest, it was proving ineffective. Professor Sáez Valero, along with Inmaculada Cuchillo and Inmaculada López, main authors of the study, explain that this finding opens the possibility of designing new tests applicable in the early diagnosis and clinical trials, in order to effectively estimate the value of sAPP as a biomarker for Alzheimer's.

The validation of new biomarkers for clinical diagnosis of Alzheimer's disease in its early stages is a priority for the appropriate therapeutic intervention of disease. Furthermore, there is a need to find biochemical markers in order to follow the development of clinical trials for the design of new treatments. In this field studying sAPP and its fragments could be extremely useful.

The research group of Professor Sáez Valero also belongs to the Centre of Biomedical Research in Neurodegenerative Diseases (CIBERNED), an initiative of the Instituto de Salud Carlos III to combat neurodegenerative and neurological diseases. Sáez Valero stresses that this work has been possible thanks to the collaboration of other researchers: as well as the members of his team, including Alba Boix, he had the collaboration of José Luis Molinuevo, neurologist at the Hospital Clínic of Barcelona, and Gunnar Brinkmalm and Kaj Blennow, researchers at the Department of Psychiatry and Neurochemistry, University of Gothenburg (Sweden).


Story Source:

Materials provided by Asociación RUVID. Note: Content may be edited for style and length.


Journal Reference:

  1. Cuchillo-Ibañez et al. Heteromers of amyloid precursor protein in cerebrospinal fluid. Molecular Neurodegeneration, 2015 DOI: 10.1186/1750-1326-10-2

Cite This Page:

Asociación RUVID. "New biomarkers for the diagnosis of Alzheimer’s." ScienceDaily. ScienceDaily, 4 February 2015. <www.sciencedaily.com/releases/2015/02/150204075222.htm>.
Asociación RUVID. (2015, February 4). New biomarkers for the diagnosis of Alzheimer’s. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/02/150204075222.htm
Asociación RUVID. "New biomarkers for the diagnosis of Alzheimer’s." ScienceDaily. www.sciencedaily.com/releases/2015/02/150204075222.htm (accessed May 23, 2017).

RELATED STORIES